Friday, June 3, 2022

Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers reported.

from Latest Science News -- ScienceDaily https://ift.tt/0LH9PVY
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists found the “holy grail” gene that could one day help humans regrow limbs

Scientists studying axolotls, zebrafish, and mice have uncovered a shared set of genes that may one day help humans regrow lost limbs. By id...